References
- Taylor P, Radić Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol 1994;33:281–320.
- Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo Californica: a prototypic acetylcholine-binding protein. Science 1991;253:872–97.
- Kovarik Z. Amino acid residues conferring specificity of cholinesterases. Period Biol 1999;101:7–15.
- Radić Z, Pickering NA, Vellom DC, et al. Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors. Biochemistry 1993;32:12074–84.
- Saxena A, Redman AMG, Jiang X, et al. Differences in active-site gorge dimensions of cholinesterase revealed by binding of inhibitors to human butyrylcholinesterase. Chem Biol Interact 1999;119 – 120:61–9.
- Taylor P, Radić Z, Hosea NA, et al. Structural bases for the specificity of cholinesterase catalysis and inhibition. Toxicol Lett 1995;82 – 83:453–8.
- Soreq H, Seidman S. Acetylcholinesterase – new roles for an old actor. Nat Rev Neurosci 2001;2:294–302.
- Silman I, Sussman JL. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Curr Opin Pharmacol 2005;5:293–302.
- Pienica C, Soreq H. MicroRNA regulators of cholinergic signaling link neuromuscular, cardiac and metabolic systems. Period Biol 2016;118:373–9.
- Chatonnet A, Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem J 1989;260:625–34.
- Çokugras AN. Butyrylcholinesterase: structure and physiological importance. Turk J Biochem 2003;28:54–61.
- Mesulam MM, Guillozet A, Shaw P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002;110:627–39.
- Guillozet AL, Mesulam M-M, Smiley JF, Mash DC. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42:909–18.
- Mesulam MM, Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722–7.
- Darvesh S, Walsh R, Kumar R, et al. Inhibition of human cholinesterases by drugs used to treat alzheimer disease. Alzheimer Dis Assoc Disord 2003;17:117–26.
- Bosak A, Ramić A, Šmidlehner T, et al. Design and evaluation of selective butyrylcholinesterase inhibitors based on Cinchona alkaloid scaffold. PLoS One 2018;13:e0205193.
- Bosak A, Opsenica DM, Šinko G, et al. Structural aspects of 4-aminoquinolines as reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase. Chem Biol Interact 2019;308:101–9.
- Katalinić M, Bosak A, Kovarik Z. Flavonoids as inhibitors of human butyrylcholinesterase variants. Food Technol Biotechnol 2014;52:64–7.
- Šagud I, Škorić I, Burčul F. Naphthoxazoles and heterobenzoxazoles: cholinesterase inhibiting and antioxidant activity. Turk J Chem 2019;43:118–24.
- Šagud I, Šindler-Kulyk M, Škorić I, et al. Synthesis of naphthoxazoles by photocyclization of 4-/5-(phenylethenyl)oxazoles. Eur J Org Chem 2018;2018:3326–35.
- Fors BP, Krattiger P, Strieter E, Buchwald SL. Water-mediated catalyst preactivation: an efficient protocol for C-N cross-coupling reactions. Org Lett 2008;10:3505–8.
- Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res 2004;50:433–40.
- Kumar A, Darreh-Shori T. DMSO: a mixed-competitive inhibitor of human acetylcholinesterase. ACS Chem Neurosci 2017;8:2618–25.
- Van Leusen AM, Hoogenboom BE, Siderius H. A novel and efficient synthesis of oxazoles from tosylmethylisocyanide and carbonyl compounds. Tetrahedron Letters 1972;13:2369–72.
- Cochran R, Kalisiak J, Küçükkilinç T, et al. Oxime-assisted acetylcholinesterase catalytic scavengers of organophosphates that resist aging. J Biol Chem 2011;286:29718–24.
- Ellman GL, Courtney KD, Andres V, Jr., Featherstone RM. New and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95.